

UK MARKETING AUTHORISATIONS

FOR SALE

CEFUROXIME SODIUM FOR
INFUSION AND INJECTION

A PRODUCT GROWING
IN DEMAND

**OFFERS CLOSING DATE
14TH JANUARY 2022**

A unique and rare opportunity to purchase three UK marketing authorisations for front line hospital treatment of infections. There is also private hospital use as well as export.

IPG is pleased to be exclusively offering these three MAs for sale.



Cefuroxime Sodium for Infusion and Injection in three strengths 250mg, 750mg and 1,500mg presentations.

Further information

Each MA is live with the MHRA. The site of manufacture is based in China with current GMP certificate and IPG have available the last audit inspection report for FDF and API. PV is active and maintained. There are not many active MAs for this product in the UK and certainly none with non-EU reliant suppliers for the finished product or the API.

Cefuroxime Sodium is also used in France and Scandinavia as well as the UK, Ireland and the USA. The dossier is owned outright, and licensing rights can be granted for any Territories the buyer may require. Purchase of the UK MA's does not automatically grant rights to exploit the IP outside of the UK. IPG are able to support the buyer after MA or Dossier purchase with a range of services.

Contact us

Express your interest by emailing info@icepharmagroup.com with `Cefuroxime` as the heading. Where after CDA execution, we can provide MA Grant Letters as proof of MA.

How the process works

We are prepared to answer five initial questions. Depending on the level of interest it is likely we may enter closed envelope bidding for the product, and we will set a reserve price, with a closing date of 14th January 2022. If your interest is such that you wish to make an immediate offer subject to contract please make this wish known in the email.